The panel / The causes nobody else checks

CBC and CMP

This is the safety test. Testosterone drives red blood cell production, and if the blood thickens far enough it carries clot risk. There are specific numbers at which therapy is reduced or stopped, and a clinic that cannot tell you what they are is not monitoring you.

What it measures

The blood count covers red cells, white cells and platelets, and gives the haematocrit, which is the proportion of your blood made up of red cells. The metabolic panel covers kidney function, liver enzymes, electrolytes and albumin. Albumin is not incidental here, since it is a required input for calculating free testosterone.

What matters here

HaematocritThe number that governs testosterone therapy

HaemoglobinFlags anaemia, which is its own cause of fatigue

AlbuminNeeded from the metabolic panel to calculate free testosterone

Baseline matters as much as monitoring. A haematocrit above 48 percent before starting is a relative contraindication to therapy, not something to discover three months in.

Why it is on the panel

Because raising red cell production is the most predictable effect testosterone has, and it is the one that requires ongoing attention rather than a single check. It also catches anaemia, kidney and liver disease, which produce fatigue on their own and change what is safe to prescribe.

How it is measured

SpecimenWhole blood and serum

FastingYes, alongside glucose and testosterone

BaselineBefore therapy starts

ThenAt 3 to 6 months

ThenAnnually

TurnaroundTypically 1 to 2 days

Interpretation

Reading the result

The haematocrit thresholds are the numbers worth knowing, and they are not negotiable clinical preferences.

Bands used in practice

Above 48 percent at baselineA relative contraindication to starting therapy.

Rising but under 54 percentMonitored, with dose and formulation reviewed.

Above 54 percentTherapy stops until it falls, then restarts at a reduced dose.

Low haemoglobinAnaemia, which is its own explanation for fatigue and needs its own workup.

Above 54 percent, the response is to stop, look for hypoxia and sleep apnoea as contributors, and resume at a lower dose once it settles. Therapeutic phlebotomy is also effective. Some sources apply a more conservative 50 percent threshold for withholding, which is a reasonable difference of practice rather than a contradiction.

What moves these numbers

6 things that move it

Testosterone dose and formulation. Injectable preparations raise haematocrit more than gels.

Untreated sleep apnoea, which raises haematocrit through nocturnal hypoxia. It compounds directly with therapy.

Smoking, and living at altitude.

Dehydration, which concentrates the sample and can falsely raise haematocrit.

Iron deficiency, which lowers haemoglobin and can mask a rise.

Alcohol and medications, which move liver enzymes independently of any hormone.

What happens next

A raised baseline haematocrit is investigated before therapy rather than treated as an obstacle to work around. Sleep apnoea is the common finding.

A haematocrit above 54 on therapy means holding the dose, not adjusting it slightly and hoping.

Kidney or liver abnormalities are worked up on their own merits, since both cause fatigue and both affect drug handling.

Anaemia prompts iron studies, and in an adult man that usually means looking for a source of blood loss.

Straight answers

It stimulates red cell production, which is a normal androgen effect rather than a side effect in the usual sense. In moderation it is harmless. Past a certain point the blood becomes viscous enough to raise clot risk, which is why the haematocrit is tracked at baseline, at three to six months, and yearly, and why there is a hard number at which we stop.